BVTV: Biogen’s Alzheimer's drug might exceed Wall Street expectations
Reuters, 30 Sep 2022
Biogen’s market value rose $11 bln on news its new treatment for Alzheimer's disease appeared effective. Robert Cyran explains why this rise is rather cautious, and how the drug might exceed Wall Street’s assumptions.
Reuters brings you the latest business, finance and breaking news video from around the globe. Our reputation for accuracy and impartiality is unparalleled.
Get the latest news on: http://reuters.com/
Follow Reuters on Facebook: https://www.facebook.com/Reuters
Follow Reuters on Twitter: https://twitter.com/Reuters
Follow Reuters on Instagram: https://www.instagram.com/reuters/?hl=en